United Therapeutics Corporation - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 67

United Therapeutics Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “United Therapeutics Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- United Therapeutics Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of United Therapeutics Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of United Therapeutics Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the United Therapeutics Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate United Therapeutics Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of United Therapeutics Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the United Therapeutics Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with United Therapeutics Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of United Therapeutics Corporation and identify potential opportunities in those areas.

List of Tables
List of Figures
United Therapeutics Corporation Snapshot
United Therapeutics Corporation Overview
Key Information
Key Facts
United Therapeutics Corporation – Research and Development Overview
Key Therapeutic Areas
United Therapeutics Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
United Therapeutics Corporation – Pipeline Products Glance
United Therapeutics Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
United Therapeutics Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
United Therapeutics Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
United Therapeutics Corporation – Drug Profiles
Oral Remodulin_
Product Description
Mechanism of Action
R&D Progress
Oral Treprostinil
Product Description
Mechanism of Action
R&D Progress
3F8 Mab
Product Description
Mechanism of Action
R&D Progress
Aviptadil
Product Description
Mechanism of Action
R&D Progress
Oral Remodulin_
Product Description
Mechanism of Action
R&D Progress
Oral Treprostinil
Product Description
Mechanism of Action
R&D Progress
UT-231B
Product Description
Mechanism of Action
R&D Progress
8H9 MAb
Product Description
Mechanism of Action
R&D Progress
Oral Treprostinil
Product Description
Mechanism of Action
R&D Progress
Glycobiology Antiviral Agents
Product Description
Mechanism of Action
R&D Progress
United Therapeutics Corporation – Pipeline Analysis
United Therapeutics Corporation – Pipeline Products by Therapeutic Class
United Therapeutics Corporation Pipeline Products By Target
United Therapeutics Corporation – Pipeline Products by Route of Administration
United Therapeutics Corporation – Pipeline Products by Molecule Type
United Therapeutics Corporation – Company Statement
United Therapeutics Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 01, 2010: United Therapeutics And Lee's Pharmaceutical Sign Remodulin Distribution Agreement For China
Feb 19, 2010: United Therapeutics Withdraws EU Marketing Authorization Application For Tyvaso For Treatment Of Pulmonary Arterial Hypertension
Dec 11, 2009: Launch of once-daily-available “adcirca Tablets 20mg” for the treatment of pulmonary arterial hypertension
Jul 31, 2009: FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
Jul 31, 2009: FDA Approves TYVASO (Treprostinil) Inhalation Solution For The Treatment Of Pulmonary Arterial Hypertension
May 26, 2009: FDA Approves ADCIRCA(Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Apr 28, 2009: U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months
Mar 16, 2009: United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
Nov 17, 2008: Freedom-C Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Fails To Meet Primary Endpoint
Mar 27, 2007: United Therapeutics And Mochida Pharmaceutical Sign Remodulin Distribution Agreement For Japan
Financial Deals Landscape
United Therapeutics Corporation, Deals Volume Summary, 2004 to YTD 2010
United Therapeutics Corporation, Deals Summary By Region, 2004 to YTD 2010
United Therapeutics Corporation, Deals Summary, 2004 to YTD 2010
United Therapeutics Corporation Detailed Deal Summary
Debt Offering
United Therapeutics Completes Private Placement Of $250 Million
Lung Rx Enters Into An Agreement With mondoBIOTECH
Lung Rx Enters Into An Agreement With mondoBIOTECH
Aradigm And Lung Rx Enter Into License Agreement
United Therapeutics Enters Into Co-Marketing Agreement With Mochida Pharmaceutical
Aradigm Enters Into Co-Development Agreement With United Therapeutics
Licensing Agreements
United Therapeutics Enters Into Licensing Agreement With Eli Lilly
United Therapeutics Enter Into Licensing Agreement With Memorial Sloan Kettering Cancer Center
Lung Rx Amends Licensing Agreement With Toray Industries
Lung Rx Enters Into Licensing Agreement With Northern Therapeutics
Supernus Pharmaceuticals Enters Into A Licensing Agreement With United Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• International Military and Government Helicopter Survey
• Charter Schools - Global Outlook
• Electronic Warfare Systems - Global Strategic Business Report